|
gptkbp:instanceOf
|
gptkb:brand
gptkb:contraceptive_device
|
|
gptkbp:activeIngredient
|
gptkb:etonogestrel
ethinylestradiol
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:canBeStoredAtRoomTemperature
|
up to 4 months
|
|
gptkbp:category
|
gptkb:hormonal_contraceptive
|
|
gptkbp:duration
|
3 weeks per cycle
|
|
gptkbp:effect
|
about 91% with typical use
over 99% with perfect use
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:etonogestrel/ethinylestradiol_vaginal_ring
|
|
gptkbp:insertionFrequency
|
once every 4 weeks
|
|
gptkbp:manufacturer
|
gptkb:Organon
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:United_States
|
|
gptkbp:notRecommendedFor
|
women over 35 who smoke
women with history of blood clots
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:productType
|
vaginal ring
|
|
gptkbp:removalFrequency
|
once every 3 weeks
|
|
gptkbp:riskFactor
|
heart attack
stroke
blood clots
|
|
gptkbp:routeOfAdministration
|
vaginal
|
|
gptkbp:sideEffect
|
nausea
headache
breast tenderness
mood changes
vaginal irritation
|
|
gptkbp:storage
|
2-8°C (refrigerated)
|
|
gptkbp:usedFor
|
birth control
contraception
|
|
gptkbp:website
|
https://www.nuvaring.com/
|
|
gptkbp:bfsParent
|
gptkb:Organon_Pharmaceuticals
gptkb:MRK
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NuvaRing
|